Neoplasm by Special Category

In patients with myelodysplastic syndrome, in a multivariate analysis those with mutations in TP53 had shorter overall survival than wild-type patients.

PMID 24836762 · Bally et al., 2014 · Open in CIViC

Tumors from 114 patients with head and neck squamous cell carcinoma were analyzed for TP53 mutations, 21 of which were treated with surgery. Unlike those treated with radiotherapy, those treated with … (full text at CIViC)

PMID 11325447 · Alsner et al., 2001 · Open in CIViC

Tumors from 114 patients with head and neck squamous cell carcinoma were analyzed for TP53 mutations. Of the 93 patients treated with radiotherapy, patients with mutations in TP53 had lower rates of l… (full text at CIViC)

PMID 11325447 · Alsner et al., 2001 · Open in CIViC

In relapsed B-ALL patients, TP53 mutations were associated with morphologic nonresponse to therapy (>5% blasts in the bone marrow after 9 weeks of treatment) as well as reduced event free and overall … (full text at CIViC)

PMID 21747090 · Hof et al., 2011 · Open in CIViC

In a study of 97 patients with AML treated with HSCT, 40 had TP53 mutations comprising a total of 44 mutations. Patients with a TP53 mutation had a reduced three year probability of overall survival … (full text at CIViC)

PMID 26771088 · Middeke et al., 2016 · Open in CIViC

In a study of 126 patients with long-term follow-up, TP53 mutations were significantly associated with shorter median survival in patients (P = 0.002) from time of diagnosis. The median survival from … (full text at CIViC)

PMID 18689542 · Zenz et al., 2008 · Open in CIViC

In a study of 439 patients with myelodysplastic syndrome, patients with TP53 mutations (N=33) has worse overall survival than wildtype patients (N=406) (P<0.001 univariate). This difference was also o… (full text at CIViC)

PMID 21714648 · Bejar et al., 2011 · Open in CIViC

This study showed that patients with TP53 mutated medulloblastoma (8/49, 16%) exhibited worse prognosis compared to those with wildtype medulloblastoma (41/49, 84%). A 5-year overall survival of 0% wa… (full text at CIViC)

PMID 20142599 · Tabori et al., 2010 · Open in CIViC

This study examined the prognostic implication of TP53 mutation status in different molecular subgroups of medulloblastoma. A discovery cohort of 397 patients and a validation cohort of 156 cases were… (full text at CIViC)

PMID 23835706 · Zhukova et al., 2013 · Open in CIViC

One of the goals of this study is to understand the biology of the sonic-hedgehog subgroup of medulloblastoma (SHH-MB) across different age groups. A large cohort of patients (n=133) with SHH-MB, incl… (full text at CIViC)

PMID 24651015 · Kool et al., 2014 · Open in CIViC

In breast cancer patients harboring TP53 mutation, mutations in conserved regions such as R249 are prognostic for a worse overall survival compared to those harboring wild-type TP53. Multivariate Cox … (full text at CIViC)

PMID 9569050 · Berns et al., 1998 · Open in CIViC

Unlike other studies, in this study of 110 patients with head and neck squamous cell carcinoma, there was no significant difference in the overall survival of patients with and without any TP53 mutati… (full text at CIViC)

PMID 8901856 · Koch et al., 1996 · Open in CIViC

A study of 53 patients with B-CLL found a significant resistance to chemotherapy and corresponding poor clinical outcomes among the 7 treated patients with p53 mutations compared to the 29 treated pat… (full text at CIViC)

PMID 8241511 · el Rouby et al., 1993 · Open in CIViC

In the CLL4 trial assessing first line treatment with chlorambucil or fludarabine with or without cyclophosphamide, patients with TP53 mutations experienced poorer overall response rates (27% vs 83%),… (full text at CIViC)

PMID 21483000 · Gonzalez et al., 2011 · Open in CIViC

In an analysis of 321 patients with lung adenocarcinoma who received potentially curative pulmonary resection, patients with TP53 mutated tumors (N=115, exons 4-10 evaluated) had significantly poorer … (full text at CIViC)

PMID 19096302 · Kosaka et al., 2009 · Open in CIViC

Analysis of 135 patients with chemotherapy naive lung adenocarcinoma, TP53 mutations were associated with reduced progression free survival (p = 0.0014, log rank test) using primary resection specimen… (full text at CIViC)

PMID 22980975 · Imielinski et al., 2012 · Open in CIViC

In a trial of 68 glioblastoma patients treated with either temozolomide or semustine, 24 patients were found to have TP53 mutations at codons 175, 248, or 273. Patients with TP53 mutation were found t… (full text at CIViC)

PMID 24248532 · Wang et al., 2014 · Open in CIViC

TP53 mutation was shown to be associated with shorter overall survival in patients with adrenocortical tumors (log-rank test; P=0.098). Of 20 patients studied, 5 had coding mutation in TP53. Four of t… (full text at CIViC)

PMID 15922892 · Sidhu et al., 2005 · Open in CIViC

Described in many studies

PMID 30617194 · Grande et al., 2019 · Open in CIViC

This study confirmed clinical associations between TP53 and NOTCH1 with poor outcome.

PMID 32160292 · Pararajalingam et al., 2020 · Open in CIViC

This study used a combination of RNA-seq, whole genome and targeted sequencing to identify recurrently mutated genes in follicular and diffuse large B-cell lymphoma. They reported 30 genes that had si… (full text at CIViC)

PMID 21796119 · Morin et al., 2011 · Open in CIViC

Through a meta-analysis of exome and whole genome sequencing data, this study identified 18 genes that were significantly enriched for mutations in MCL (including TP53).

PMID 32160292 · Pararajalingam et al., 2020 · Open in CIViC

Thirty-six patients with CLL were treated with alemtuzumab. Partial or complete response was achieved in 6 of 15 patients with p53 mutations, compared to 4 of 21 without. These findings are not statis… (full text at CIViC)

PMID 14726385 · Lozanski et al., 2004 · Open in CIViC

In this meta-analysis of 13 studies (564 patients) p53 positivity as defined by high protein expression and/or p53 mutation was associated with improved response to chemotherapy (risk ratio [RR] = 0.7… (full text at CIViC)

PMID 24740294 · Xu et al., 2014 · Open in CIViC

A clinical trial comparing selumetinib and docetaxel vs. docetaxel and placebo in KRAS mutant NSCLC was recapitulated in mice. Tumors were induced in lung epithelium by nasal instillation of CRE-beari… (full text at CIViC)

PMID 22425996 · Chen et al., 2012 · Open in CIViC

In this preclinical study, MMTV-Wnt1 mammary tumors with mutant TP53 showed a better clinical response to chemotherapy (doxorubicin) than TP53 wild-type tumors. This was mediated by wild-type TP53-ind… (full text at CIViC)

PMID 22698404 · Jackson et al., 2012 · Open in CIViC

In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment o… (full text at CIViC)

PMID 14514923 · Bataille et al., 2003 · Open in CIViC

This study examined the combined effects of APR-246 and doxorubicin in doxorubicin-resistant ovarian cancer cell lines. It revealed a decrease in IC50 value for doxorubicin from 0.95±0.11 μM to 0.12±0… (full text at CIViC)

PMID 26086967 · Mohell et al., 2015 · Open in CIViC

In this phase 1/2 clinical trial, 55 patients (40 MDS, 11 AML, 4 MDS/myeloproliferative neoplasms) with myelodysplastic syndromes harbouring TP53 mutations were treated with a combination of eprenetap… (full text at CIViC)

PMID 33449813 · Sallman et al., 2021 · Open in CIViC

The combination effect of APR-246 and cisplatin was studied in cisplatin-resistant ovarian cancer cell lines. A decrease in IC50 value from 52±11 to 3.2±0.8 μM (p <0.05) for cisplatin was recorded in… (full text at CIViC)

PMID 26086967 · Mohell et al., 2015 · Open in CIViC

In this phase 1b study, the combination treatment of eprenetapopt (APR-246) and pembrolizumab was investigated for its efficacy in patients with advanced or metastatic solid tumors. Out of the 37 pati… (full text at CIViC)

PMID 36084396 · Park et al., 2022 · Open in CIViC

In this retrospective analysis, tumor samples from 101 patients from the CONKO-001 trial, who received curatively intended surgery for pancreatic adenocarcinoma (PDAC) followed by adjuvant chemotherap… (full text at CIViC)

PMID 32234756 · Sinn et al., 2020 · Open in CIViC

In a study 202 breast cancer patients undergoing tamoxifen treatment, a higher frequency of wildtype TP53 patients responded to treatment compared to those with mutations in TP53 (66% wild-type vs. 31… (full text at CIViC)

PMID 10786679 · Berns et al., 2000 · Open in CIViC

In a trial of 68 glioblastoma patients treated with either temozolomide or semustine, 24 patients were found to have TP53 mutations at codons 175, 248, or 273. Kaplan-Meier analysis of the 35 patients… (full text at CIViC)

PMID 24248532 · Wang et al., 2014 · Open in CIViC

In this trial involving 500 patients, 188 individuals received treatment with VEGF/VEGFR inhibitors. Among them, 106 patients had tumors containing TP53 mutations. The analysis revealed a higher rate … (full text at CIViC)

PMID 27466356 · Wheler et al., 2016 · Open in CIViC

In patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, patients with deletion 17p and/or mutations in TP53 (N=24) were not more likely to have progressive dis… (full text at CIViC)

PMID 28473407 · Anderson et al., 2017 · Open in CIViC

In patients with relapsed /refractory chronic lymphocytes leukemia or small lymphocytic lymphoma, patients with deletion 17p and/or mutations in TP53 (N=24) were not more likely to have progressive di… (full text at CIViC)

PMID 28473407 · Anderson et al., 2017 · Open in CIViC

Two phase II studies (PBTC-025B, n=31, age ≥ 22 years; PBTC-032, n=12, age 3-21 years) assessed the targeted efficacy of vismodegib, an SMO inhibitor, in patients with recurrent sonic hedgehog subgrou… (full text at CIViC)

PMID 26169613 · Robinson et al., 2015 · Open in CIViC

40 diffuse anaplasia in Wilms tumours (DAWT) samples were tested using copy number (n = 32) and gene expression (n = 36) arrays. 22 had TP53 mutations and 20 of these also had 17p loss. An increased r… (full text at CIViC)

PMID 25313908 · Maschietto et al., 2014 · Open in CIViC

p53 overexpression (>10% positive stained nuclei) was found in 110 cases from a 178 patient cohort with invasive ovarian carcinoma who had undergone surgery. Overexpression of p53 was correlated with … (full text at CIViC)

PMID 11595686 · Reles et al., 2001 · Open in CIViC

44 archival FFPE samples from confirmed cases of Wilms tumor with mean age 3 years 2 months, and taken from the most histologically aggressive parts of each tumor, were stained with p53 monoclonal ant… (full text at CIViC)

PMID 21525573 · Jadali et al., 2011 · Open in CIViC

In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC)

PMID 22256804 · Su et al., 2012 · Open in CIViC

The P47S (rs1800371) variant of TP53 is observed in 1.5% in African Americans and between 6% and 8% in certain African populations but has not been detected in Caucasian Americans. This paper reports … (full text at CIViC)

PMID 27034505 · Jennis et al., 2016 · Open in CIViC

Pooled data from 13 studies of patients with lung cancer found little effect of codon 72 allele on the overall survival of patients with lung cancer. Proline homozygous patients were correlated with s… (full text at CIViC)

PMID 12840112 · Matakidou et al., 2003 · Open in CIViC

In a relatively small meta-analysis of 119 women with cervical cancer and 127 controls, associations with homozygosity for arginine, and heterozygosity at this locus were both associated with odds rat… (full text at CIViC)

PMID 11535556 · Klug et al., 2001 · Open in CIViC

Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP… (full text at CIViC)

PMID 25730903 · Saiki et al., 2015 · Open in CIViC

Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP… (full text at CIViC)

PMID 25730903 · Saiki et al., 2015 · Open in CIViC